Skip to content
OpenCapital
Get started

Zymeworks ZYME Royalties — Research and development collaborations

Other product segments

Recognition of deferred revenue
$0—

Similar metrics at other companies

Ultragenyx Pharmaceutical logo
RARECollaboration And Royalty — Revenue
$93M-9.7%
Nurix Therapeutics, Inc. logo
NRIXCollaboration revenue — Revenue
$6.25M-66.1%
Aurinia Pharmaceuticals logo
AUPHLicense, collaboration and royalty revenue — Revenue
$4.14M+66.1%
Tarsus Pharmaceuticals, Inc. logo
TARSLicense fees and collaboration revenue — Total revenues
$16.67M—
Vir Biotechnology, Inc. logo
VIRLicense and collaboration revenue — Total revenues
-$41K+41.4%
Ligand Pharmaceuticals logo
LGNDRoyalties — Total revenues and income
$42.96M+56.3%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's royalties — research and development collaborations.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's royalties — research and development collaborations?
Zymeworks (ZYME) reported royalties — research and development collaborations of $1.33M in Q1 2026.
How has Zymeworks's royalties — research and development collaborations changed year-over-year?
Zymeworks's royalties — research and development collaborations increased by 558.4% year-over-year, from $202K to $1.33M.
What does royalties — research and development collaborations mean?
This metric represents revenue recognized from research and development collaboration agreements within the royalties segment. It reflects the financial value generated through partnerships where the company provides its proprietary technology platforms or expertise to external entities for drug discovery and development. This serves as an indicator of the company's ability to monetize its intellectual property and scientific capabilities through strategic alliances.